BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26887512)

  • 1. [Expression and clinical significance of MTDH and VEGF in triple-negative breast cancer].
    Tan L; Qin H; Piao Y; Liu Z; Han Y; Song F; Xie X
    Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):827-32. PubMed ID: 26887512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of metadherin protein predicts worse disease-free and overall survival in laryngeal squamous cell carcinoma.
    Liu Y; Su Z; Li G; Yu C; Ren S; Huang D; Fan S; Tian Y; Zhang X; Qiu Y
    Int J Cancer; 2013 Aug; 133(3):671-9. PubMed ID: 23364922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progranulin expression in breast cancer with different intrinsic subtypes.
    Li LQ; Min LS; Jiang Q; Ping JL; Li J; Dai LC
    Pathol Res Pract; 2012 Apr; 208(4):210-6. PubMed ID: 22397762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
    Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
    Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMPK inhibits MTDH expression via GSK3β and SIRT1 activation: potential role in triple negative breast cancer cell proliferation.
    Gollavilli PN; Kanugula AK; Koyyada R; Karnewar S; Neeli PK; Kotamraju S
    FEBS J; 2015 Oct; 282(20):3971-85. PubMed ID: 26236947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXO3a expression is associated with lymph node metastasis and poor disease-free survival in triple-negative breast cancer.
    Rehman A; Kim Y; Kim H; Sim J; Ahn H; Chung MS; Shin SJ; Jang K
    J Clin Pathol; 2018 Sep; 71(9):806-813. PubMed ID: 29588373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot Study on MAGE-C2 as a Potential Biomarker for Triple-Negative Breast Cancer.
    Zhao Q; Xu WT; Shalieer T
    Dis Markers; 2016; 2016():2325987. PubMed ID: 27843173
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
    Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
    BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Jagged1/Notch3 Signaling Pathway and their Relationship with the Tumor Angiogenesis in TNBC.
    Xue S; He L; Zhang X; Zhou J; Li F; Wang X
    Arch Med Res; 2017 Feb; 48(2):169-179. PubMed ID: 28625320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer.
    Bahhnassy A; Mohanad M; Shaarawy S; Ismail MF; El-Bastawisy A; Ashmawy AM; Zekri AR
    Mol Med Rep; 2015 Jul; 12(1):851-64. PubMed ID: 25824321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated expression of HABP1 is a novel prognostic indicator in triple-negative breast cancers.
    Wang J; Song Y; Liu T; Shi Q; Zhong Z; Wei W; Huang S; Pang D
    Tumour Biol; 2015 Jun; 36(6):4793-9. PubMed ID: 25794640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis.
    Lee HJ; Kim JY; Song IH; Park IA; Yu JH; Gong G
    Oncology; 2015; 89(6):337-44. PubMed ID: 26413775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression analysis of E-cad and vascular endothelial growth factor in triple-negative breast cancer patients of different ethnic groups in western China.
    Jiang W; Li Y; Ou J; Wang X; Zhang C; Yi L; Xue L; Zhang M
    Medicine (Baltimore); 2017 Oct; 96(42):e8155. PubMed ID: 29049198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.
    Abdelrahman AE; Rashed HE; Abdelgawad M; Abdelhamid MI
    Ann Diagn Pathol; 2017 Jun; 28():43-53. PubMed ID: 28648939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of Cystatin E/M with Clinicopathological Features and Prognosis in Triple-Negative Breast Cancer.
    Li Q; Zheng ZC; Ni CJ; Jin WX; Jin YX; Chen Y; Zhang XH; Chen ED; Cai YF
    Ann Clin Lab Sci; 2018 Jan; 48(1):40-44. PubMed ID: 29530995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relation of lymphatic microvessel density detected by monoclonal antibody D2-40 with VEGF-C expression in breast cancer].
    Xie XD; Qu SX; Zheng ZD; Song FL; Liu DW
    Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):356-60. PubMed ID: 18953835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancer.
    Maierthaler M; Kriegsmann M; Peng C; Jauch S; Szabo A; Wallwiener M; Rom J; Sohn C; Schneeweiss A; Sinn HP; Yang R; Burwinkel B
    Exp Mol Pathol; 2015 Aug; 99(1):180-7. PubMed ID: 26112095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
    Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.